{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:57:44Z","timestamp":1793775464635,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To externally validate an FDA-approved artificial intelligence (AI) tool for detecting heart failure with preserved ejection fraction (HFpEF) using echocardiographic video clips, comparing its performance to invasive haemodynamic criteria in a real-world referral cohort with unexplained dyspnoea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 47 patients who underwent transthoracic echocardiography (TTE) and right heart catheterization (RHC), including 28 with both rest and exercise haemodynamics. The AI model evaluated apical 4-chamber video data and classified outputs as HFpEF, no HFpEF, or non-diagnostic, without any other clinical data. The primary outcome was invasively defined HFpEF: pulmonary capillary wedge pressure (PCWP) \u226515\u2005mmHg at rest or \u226525\u2005mmHg with exercise. Secondary analysis used a PCWP\/cardiac output (CO) slope &amp;gt;2\u2005mmHg\/L\/min. We assessed sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients with exercise RHC (n = 28), 71% met haemodynamic HFpEF criteria. The AI tool demonstrated sensitivity of 30%, specificity of 88%, PPV of 86%, and NPV of 33%. Using the PCWP\/CO slope (n = 25), specificity and PPV were 100%, sensitivity 27%, and NPV 16%. AI-positive patients had significantly higher resting PCWP (20 vs 15\u2005mmHg, P = .029), mean PA pressure (29 vs 24\u2005mmHg, P = .02), and PVR (2.1 vs 1.3 WU, P = .002). In patients with indeterminate H2FPEF scores (n = 25), the AI correctly identified 80% of those with invasively confirmed HFpEF. Model performance was consistent across TTE-RHC intervals &amp;lt;365 and &amp;lt;90 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This AI model demonstrated high specificity and positive predictive value (PPV) for detecting HFpEF, reliably identifying patients with more advanced haemodynamic abnormalities. Its performance remained robust across variable intervals between transthoracic echocardiography (TTE) and right heart catheterization (RHC), and in patients with indeterminate clinical scores. Due to limited sensitivity, the tool is best utilized to enrich identification of patients with clearly abnormal haemodynamics rather than to exclude HFpEF, particularly in early or borderline cases. While broader use as a screening tool is promising, prospective validation studies are necessary to confirm its utility in general populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag052","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:46:46Z","timestamp":1775216806000},"source":"Crossref","is-referenced-by-count":1,"title":["Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction"],"prefix":"10.1093","volume":"13","author":[{"given":"Ryan","family":"Sachar","sequence":"first","affiliation":[{"name":"Section of General Internal Medicine, University of Chicago Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Latz","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine , 5841 South Maryland Avenue, MC 6092 Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Allan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E","family":"Blair","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Kim","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine , 5841 South Maryland Avenue, MC 6092 Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Grinstein","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine , 5841 South Maryland Avenue, MC 6092 Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Woodward","sequence":"additional","affiliation":[{"name":"Ultromics Ltd , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lang","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine , 5841 South Maryland Avenue, MC 6092 Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9489-4572","authenticated-orcid":false,"given":"Mark N","family":"Belkin","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine , 5841 South Maryland Avenue, MC 6092 Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2026040913493097100_xvag052-B1","doi-asserted-by":"publisher","first-page":"e002477","DOI":"10.1161\/JAHA.115.002477","article-title":"Clinical phenotypes in heart failure with preserved ejection fraction","volume":"5","author":"Samson","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026040913493097100_xvag052-B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.hfc.2014.04.003","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"10","author":"Andersson","year":"2014","journal-title":"Heart Fail Clin"},{"key":"2026040913493097100_xvag052-B3","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1161\/CIRCULATIONAHA.117.031622","article-title":"Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"137","author":"Pandey","year":"2018","journal-title":"Circulation"},{"key":"2026040913493097100_xvag052-B4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026040913493097100_xvag052-B5","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026040913493097100_xvag052-B6","doi-asserted-by":"publisher","first-page":"e021165","DOI":"10.1161\/JAHA.121.021165","article-title":"Validation of the 2016 ASE\/EACVI Guideline for diastolic dysfunction in patients with unexplained dyspnea and a preserved left ventricular ejection fraction","volume":"10","author":"van de Bovenkamp","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026040913493097100_xvag052-B7","doi-asserted-by":"publisher","first-page":"e023189","DOI":"10.1161\/JAHA.121.023189","article-title":"Faltering under pressure: limitations to noninvasive diastolic function assessments","volume":"10","author":"MacNamara","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026040913493097100_xvag052-B8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ehjci\/jex067","article-title":"Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study","volume":"18","author":"Lancellotti","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026040913493097100_xvag052-B9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026040913493097100_xvag052-B10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjci\/jex252","article-title":"Impact of the 2016 ASE\/EACVI recommendations on the prevalence of diastolic dysfunction in the general population","volume":"19","author":"Almeida","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026040913493097100_xvag052-B11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026040913493097100_xvag052-B12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026040913493097100_xvag052-B13","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2021 Mar 31;42(13):1274]","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026040913493097100_xvag052-B14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026040913493097100_xvag052-B15","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.jacadv.2023.100452","article-title":"Automated echocardiographic detection of heart failure with preserved ejection fraction using artificial intelligence","volume":"2","author":"Akerman","year":"2023","journal-title":"JACC Adv"},{"key":"2026040913493097100_xvag052-B16","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1038\/s41467-025-58283-7","article-title":"External validation of artificial intelligence for detection of heart failure with preserved ejection fraction","volume":"16","author":"Akerman","year":"2025","journal-title":"Nat Commun"},{"key":"2026040913493097100_xvag052-B17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.cardfail.2024.02.010","article-title":"Unmasking HFpEF with artificial intelligence: a disruptive opportunity for disease detection","volume":"30","author":"Karnik","year":"2024","journal-title":"J Card Fail"},{"key":"2026040913493097100_xvag052-B18","first-page":"29","article-title":"The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction","volume":"11","author":"Ozcan","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"key":"2026040913493097100_xvag052-B19","doi-asserted-by":"publisher","first-page":"e004750","DOI":"10.1161\/CIRCHEARTFAILURE.117.004750","article-title":"Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure","volume":"11","author":"Eisman","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026040913493097100_xvag052-B20","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/eurheartj\/ehu315","article-title":"Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction","volume":"35","author":"Dorfs","year":"2014","journal-title":"Eur Heart J"},{"key":"2026040913493097100_xvag052-B21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J Card Fail"},{"key":"2026040913493097100_xvag052-B22","doi-asserted-by":"publisher","first-page":"17455057221140209","DOI":"10.1177\/17455057221140209","article-title":"Sex differences in heart failure with preserved ejection fraction: from traditional risk factors to sex-specific risk factors","volume":"18","author":"Kaur","year":"2022","journal-title":"Womens Health (Lond)"},{"key":"2026040913493097100_xvag052-B23","doi-asserted-by":"publisher","first-page":"e004457","DOI":"10.1161\/CIRCHEARTFAILURE.117.004457","article-title":"Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the treatment of preserved cardiac function heart failure trial","volume":"11","author":"Lewis","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026040913493097100_xvag052-B24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm8060792","article-title":"Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies","volume":"8","author":"Tadic","year":"2019","journal-title":"J Clin Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/2\/xvag052\/67934766\/xvag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/2\/xvag052\/67934766\/xvag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:49:39Z","timestamp":1775756979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag052\/8626362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag052","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,3]]},"article-number":"xvag052"}}